My watch list  

10 Current news about the topic nocturia


You can refine your search further. Select from the filter options on the left to narrow down your results.

Study shows mirabegron effective and well tolerated for overactive bladder

New option for patients bothered by antimuscarinic side effects


In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder (OAB) compared to those in a placebo group. The ...


Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds


Vantia Therapeutics announced it has raised £4 million ($6.5 million) in a series B round. The round was co-led by Novo A/S and SV Life Sciences, and included MVM Life Science Partners, all existing investors in Vantia. The funds have been raised to advance the development of Vantia’s two ...


Vantia Therapeutics’ lead candidate VA106483 enters Phase IIb trial for nocturia


Vantia Therapeutics announced it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia. The study is a randomised, double-blind, placebo-controlled study and is expected to recruit approximately 120 male patients at 20 centres in the US. The study will ...


Vantia Therapeutics’ lead candidate VA106483 demonstrates positive anti-diuretic effect in Phase IIa trial in nocturia


Vantia Therapeutics announced positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased ...


Vantia Therapeutics’ pipeline continues to mature

VA106483 completes Phase IIa trial and VA111913 completes Phase I dosing


Vantia Therapeutics announced further clinical trial progress with its two lead development compounds, VA106483 for nocturia associated with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa trial of VA106483 has completed, while dosing is complete in the Phase I ...


Protox announces positive long-term data from BPH study


Protox Therapeutics Inc. announced positive results from its Phase 1 study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH), a common and bothersome urological condition among the aging male population. The results indicate that promising signs of therapeutic activity ...


BioXell confirms strong potential of Elocalcitol


At its second annual R&D Day in Zurich, BioXell presented further analysis of its Phase IIb trial data in Benign Prostatic Hyperplasia (BPH), confirming that Elocalcitol has strong potential to become a new first-line monotherapy for BPH. Current BPH first-line therapies consist of combinations ...


BioXell announces positive Phase IIb results for Elocalcitol in Benign Prostatic Hyperplasia

Primary endpoint met - Elocalcitol highly effective in arresting prostate growth


BioXell S.p.A. announced top-line results of its Phase IIb trial of Elocalcitol in Benign Prostatic Hyperplasia (BPH). The primary endpoint was met with a high degree of statistical significance, with Elocalcitol effectively arresting prostate growth. Elocalcitol also showed relevant effects on ...


BioXell Reports Preliminary Phase IIa Results in Non-Bacterial Chronic Prostatitis

Effect on pain comparable to placebo, effect observed on inflammation and lower urinary tract symptoms


BioXell S.p.A. reported preliminary results from its proof of concept trial of Elocalcitol in patients with Non-bacterial Chronic Prostatitis. The effect of Elocalcitol was found to be no different from that of placebo on the primary endpoint, focused mainly on pelvic pain. In contrast, positive ...


BioXell Plans Phase IIb European Trial for Elocalcitol in Overactive Bladder


BioXell S.p.A. announced its plans to proceed with a Phase IIb clinical trial of its lead compound Elocalcitol in Overactive Bladder (OAB). Enrolment in the pan-European study is scheduled to begin in early 2007. Details of the study design are currently being finalised. The new study follows ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE